Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
LENZ
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q2.23
N/A
-6.82
vs -3.42
Q3.23
N/A
-0.19
vs -3.09
Q4.23
N/A
-0.40
vs -3.00
Q1.24
N/A
-3.53
vs NA
Q2.24
N/A
-0.40
vs -6.82
Q3.24
N/A
-0.38
vs -0.19
Q4.24
N/A
-0.46
vs -0.40
Q1.25
N/A
-0.53
vs -3.53
Q2.25
N/A
-0.64
vs -0.40
Q3.25
N/A
-0.74
vs -0.38
Sales Growth
YoY
Current
Estimates
Q1.23
NA
NA vs NA
Q2.23
NA
NA vs NA
Q3.23
NA
NA vs NA
Q4.23
NA
NA vs NA
Q1.24
NA
NA vs NA
Q2.24
NA
NA vs NA
Q3.24
NA
NA vs NA
Q4.24
NA
NA vs NA
Q1.25
NA
NA vs NA
Q3.25
NA
2.9M vs NA
Return on Equity
QoQ
Q2.23
-25%
-0.25
vs -0.09
Q3.23
-11%
-0.11
vs -0.25
Q4.23
-12%
-0.12
vs -0.11
Q1.24
-8%
-0.08
vs -0.12
Q2.24
-5%
-0.05
vs -0.08
Q3.24
-5%
-0.05
vs -0.05
Q4.24
-6%
-0.06
vs -0.05
Q1.25
-8%
-0.08
vs -0.06
Institutionnal Ownership
QoQ
Q1.24
55
55
vs NA
NA
Q2.24
63
63
vs 55
15%
Q3.24
78
78
vs 63
24%
Q4.24
91
91
vs 78
17%
Q1.25
105
105
vs 91
15%
seekingalpha.com
8 hours ago
seekingalpha.com
10 hours ago
globenewswire.com
16 hours ago
globenewswire.com
16 hours ago
globenewswire.com
16 hours ago
Quote Panel
Key Metrics
Forecast
NaN%2026-Revenue
-415%2026-EPS
272%2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
51.00(74.00%)
Number of analyst
1
Last analyst upgrade/downgrade
Raymond James
initialisePrevious: Not converted
2024-09-26
Now: Outperform
William Blair
initialisePrevious: Not converted
2024-04-15
Now: Outperform
Citigroup
initialisePrevious: Not converted
2024-04-09
Now: Buy
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
NASDAQ
Unprofitable
Unprofitable
-0.87 ( -2.88%)
Pre-market 29.13$-0.17 (-0.60%)
Relative Strenght
Volume Buzz
-58%
Earning Acce
No
Dist 52w H.
25%Relative Strength
LENZ
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How LENZ compares to sector?
LENZ
-17x